These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 30860073

  • 1. Focal nodular hyperplasia: a weight-based, intraindividual comparison of gadobenate dimeglumine and gadoxetate disodium-enhanced MRI.
    Taibbi A, Brancatelli G, Matranga D, Midiri M, Lagalla R, Bartolotta TV.
    Diagn Interv Radiol; 2019 Mar; 25(2):95-101. PubMed ID: 30860073
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
    Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR.
    AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
    [Abstract] [Full Text] [Related]

  • 4. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients.
    Furlan A, Close ON, Borhani AA, Wu YH, Heller MT.
    Clin Radiol; 2017 Jan; 72(1):93.e1-93.e6. PubMed ID: 27633725
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ, Kim BS, Kim MJ, Kim SH, de Campos RO, Hernandes M, Semelka RC.
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M, Pigneur F, Calderaro J, Baranes L, Chiaradia M, Tselikas L, Decaens T, Costentin C, Laurent A, Azoulay D, Mallat A, Zafrani ES, Rahmouni A, Luciani A.
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison.
    Homayoon B, Diwakar H, Strovski E, Bakshi D, Harris AC, Thoeni RF, Chang SD.
    Abdom Imaging; 2014 Oct; 39(5):955-62. PubMed ID: 24676875
    [Abstract] [Full Text] [Related]

  • 11. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT, Marin D, Boll DT, Husarik DB, Davis DE, Feuerlein S, Merkle EM.
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [Abstract] [Full Text] [Related]

  • 12. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.
    Davenport MS, Caoili EM, Kaza RK, Hussain HK.
    Radiology; 2014 Jul; 272(1):123-31. PubMed ID: 24617733
    [Abstract] [Full Text] [Related]

  • 13. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY, Lee SS, Byun JH, Kim SY, Park SH, Shin YM, Lee MG.
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [Abstract] [Full Text] [Related]

  • 14. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML, Thomeer MG, Braun LMM, Gest B, van Koeverden S, Willemssen FE, Hunink M, De Man RA, Ijzermans JN, Dwarkasing RS.
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the Enhancement Pattern of Hepatic Hemangioma on Magnetic Resonance Imaging Performed With Gd-EOB-DTPA Versus Gd-BOPTA.
    Vernuccio F, Bruno A, Costanzo V, Bartolotta TV, Vieni S, Midiri M, Salvaggio G, Brancatelli G.
    Curr Probl Diagn Radiol; 2020 Mar; 49(6):398-403. PubMed ID: 31253462
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transient Severe Motion Artifact Related to Gadoxetate Disodium-Enhanced Liver MRI: Frequency and Risk Evaluation at a German Institution.
    Well L, Rausch VH, Adam G, Henes FO, Bannas P.
    Rofo; 2017 Jul; 189(7):651-660. PubMed ID: 28445909
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging With Hepatocyte-Specific Contrast Agents: Uses, Findings, and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine.
    Scali EP, Walshe T, Tiwari HA, Harris AC, Chang SD.
    Can Assoc Radiol J; 2017 Aug; 68(3):293-307. PubMed ID: 28583364
    [Abstract] [Full Text] [Related]

  • 20. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison.
    Schneider G, Maas R, Schultze Kool L, Rummeny E, Gehl HB, Lodemann KP, Kirchin MA.
    Invest Radiol; 2003 Feb; 38(2):85-94. PubMed ID: 12544071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.